drugset

Drugs / ERAS-601

Follow last change Jul 2026 re-read 9 days ago

ERAS-601

Developed for: acute myeloid leukemia · chordoma · non-small cell lung carcinoma
Investigated by: Erasca, Inc. · Memorial Sloan Kettering Cancer Center

Trials 5

today NCT06957327 · Ph 1/2 NCT05279859 · Ph 1/2 NCT04959981 · Ph 1 NCT04866134 · Ph 1/2 NCT04670679 · Ph 1

2021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT04959981	Sep 2021 → Apr 2023	non-small cell lung carcinoma	Erasca, Inc.	Completed	No outcome recorded
Phase 1	NCT04670679	Dec 2020 → Feb 2026	—	Erasca, Inc.	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT06957327	Apr 2025 → Apr 2027 expected	chordoma	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT05279859	Mar 2022 → Mar 2025	acute myeloid leukemia	Erasca, Inc.	Withdrawn	No outcome recorded Stop: Business
Phase 1/2	NCT04866134	May 2021 → Jul 2026	—	Erasca, Inc.	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2023-04-18	Erasca, Inc.	Results Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting erasca.com ↗ The combination with cetuximab was well-tolerated with favorable pharmacokinetics and no apparent drug-drug interactions.
2022-10-12	Erasca, Inc.	Results Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium erasca.com ↗ Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development
2022-09-07	Erasca, Inc.	Results Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials erasca.com ↗ today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.

All press releases naming this drug 7 releases

Date	Issuer	Release
2023-04-18	Erasca, Inc.	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting erasca.com ↗
2022-12-20	Erasca, Inc.	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors erasca.com ↗
2022-10-12	Erasca, Inc.	Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium erasca.com ↗
2022-09-07	Erasca, Inc.	Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials erasca.com ↗
2022-08-24	Erasca, Inc.	Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors erasca.com ↗
2022-07-18	Erasca, Inc.	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination erasca.com ↗
2022-04-12	Erasca, Inc.	Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting erasca.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	ERAS-601	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05279859 ↗ 4 NCT04866134 ↗ NCT06957327 ↗ NCT04670679 ↗ NCT04959981 ↗
Action	Inhibit	“ERAS-601 SHP2 Inhibitor” NCT04670679 ↗
Route	Oral	“Administered orally” NCT04670679 ↗